Content area

|
|

Håndtering af hjertekomplikationer sekundært til medicinsk kræftbehandling

Ekkokardiografisk billede til udregning af myokardiets forkortningsfraktion, hvilket primært bruges i forskningssammenhæng inden for kardioonkologien.
Forfatter(e)
Ann Banke1, Anne Polk2, Dorte Nielsen2, Lars Videbæk1, Ulrik Overgaard3, Emil Loldrup Fosbøl4, Merete Vaage-Nielsen5, Kirsten Melgaard Nielsen6 & Morten Schou5 1. Hjertemedicinsk Afdeling, Odense Universitetshospital 2. Onkologisk Afdeling, Herlev og Gentofte Hospital 3. Klinik for Blodsygdomme, Rigshospitalet 4. Hjertemedicinsk Afdeling, Rigshospitalet 5. Kardiologisk Afdeling, Herlev og Gentofte Hospital 6. Afdeling for Hjertesygdomme, Aarhus Universitetshospital Ugeskr Læger 2018;180:V04170269
Reference: 
Ugeskr Læger 2018;180:V04170269
Blad nummer: 
Sidetal: 
2-6
Management of cardiovascular complications secondary to medical treatment of cancer
As the prognoses of both heart and cancer patients have improved along with a longer life expectancy in the general population, the prevalence of both heart- and cancer diseases is increasing. Thus, a larger proportion of cancer patients will have cardiovascular co-morbidity and an increased risk of cardiovascular complications during and after cancer treatment. In this article, the current knowledge on the prevention, monitoring and treatment of cardiotoxicity induced by medical anti-cancer treatment with focus on anthracyclines, trastuzumab and 5-fluorouracil is described.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Pal Bela Szecsi | 20/01
2 kommentarer
af Peter Søndergaard | 18/01
3 kommentarer
af Mads Henrik Koch Hansen | 16/01
2 kommentarer
af Lars Guttorm | 14/01
5 kommentarer
af Morten Ellemose Gulev | 14/01
4 kommentarer
af Henning Damgaard Laugesen | 14/01
1 Kommentar
af Jette E. Hansen Kristiansen | 14/01
1 Kommentar